Search Results
Your search for The matches 34606 pages
Showing 501 - 550Risk-Reducing Surgeries Improve Survival for Younger Patients With Breast Cancer Who Are BRCA Carriers, Study Finds
Patients with early-onset breast cancer (aged 40 or younger at diagnosis) who have BRCA1 and/or BRCA2 pathogenic or likely pathogenic variants had improved overall survival by undergoing risk-reducing surgeries, including bilateral mastectomy and/or salpingo-oophorectomy, according to data...
HRQOL With Endocrine Therapy vs Radiotherapy After Breast-Conserving Surgery in Older Women With Luminal A–Like Early Breast Cancer
As reported in The Lancet Oncology by Meattini et al, interim analysis of the phase III EUROPA trial indicated that endocrine therapy was associated with poorer health-related quality of life (HRQOL) outcomes vs radiotherapy after breast-conserving surgery in women aged ≥ 70 years with luminal...
RELATIVITY-047: Extended Analysis of Overall Survival With Nivolumab/Relatlimab vs Nivolumab in Previously Untreated Advanced Melanoma
In an extended analysis of the phase II/III RELATIVITY-047 trial reported in the Journal of Oncology, Tawbi et al found a significant overall survival benefit with nivolumab/relatlimab vs nivolumab in previously untreated patients with unresectable advanced stage III or IV melanoma. The initial...
Psilocybin-Based Therapy May Address Mental Health Issues in Patients With Cancer, Addiction
Treatment with psilocybin may improve mental health issues among patients with cancer when accompanied by psychotherapy and could result in lasting, positive personality changes in patients with alcohol use disorder, according to two recent studies published by Petridis et al in Nature Mental...
Advanced Imaging May Uncover Hidden Metastases in High-Risk Prostate Cancer Cases
Researchers have found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought, according to a recent study published by Holzgreve et al in JAMA Network Open. Background Prostate-specific membrane antigen–positron-emission tomography ...
Jame Abraham, MD, FACP on the PATINA Trial
Presented by Otto Metzger, MD, on December 12, 2024, at the San Antonio Breast Cancer Symposium Discussed here by Jame Abraham, MD, FACP The phase III PATINA trial showed that the addition of palbociclib to current standard-of-care first-line maintenance therapy, following induction...
Jame Abraham, MD, FACP on the Phase III ZEST Trial
Presented by Nicholas Turner, MD, PhD, on December 13, 2024 at the San Antonio Breast Cancer Symposium Discussed here by Jame Abraham, MD, FACP The ZEST phase III clinical trial was designed to evaluate the potential of the PARP inhibitor niraparib to prevent breast cancer recurrence in...
Trends in Early-Onset Colorectal Cancer
As reported in The Lancet Oncology by Sung et al, analysis of international population-based cancer registry data indicate an increase in incidence of colorectal cancer among younger persons (age < 50 years) in a majority of countries and territories examined. Study Details Colorectal cancer...
Surgeon General’s Report Calls for Cancer Warning Labels on Alcoholic Beverages
Today, Surgeon General Dr. Vivek Murthy issued an advisory citing scientific studies linking alcoholic beverages and an increased risk of at least seven cancers, including breast and colorectal cancers, and called for alcoholic beverages to carry cancer warning labels. Health warning labels on...
New Research Approaches to Metastatic Breast Cancer
Tumor cells circulating in the blood are the germ cells of breast cancer metastases. They are rare and could not be propagated in the culture dish until now. A team from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM, and the NCT Heidelberg has now succeeded...
Novel Combination Regimen May Prevent Squamous Cell Carcinoma
A recent study by Demehri et al of Mass General Brigham investigates whether calcipotriol—a vitamin D analog—plus fluorouracil may prevent squamous cell carcinoma (SCC), with benefits lasting 5 years after treatment. This combination therapy is the first to activate specific components of the...
Addition of Nab-Paclitaxel to Gemcitabine/Cisplatin in Advanced Biliary Tract Cancers
As reported in the Journal of Clinical Oncology by Shroff et al, the phase III SWOG S1815 trial showed that nab-paclitaxel plus gemcitabine/cisplatin (GAP regimen) did not significantly improve overall survival vs gemcitabine/cisplatin alone in newly diagnosed patients with advanced biliary tract...
Novel Prognostic Tool in Hormone Receptor–Positive, HER2-Negative, Node-Positive Breast Cancer
As reported in the Journal of Clinical Oncology, Pusztai et al developed the RSClinN+ tool—an integration of the 21-gene Oncotype DX Breast Recurrence Score (RS) test and clinicopathologic factors (tumor grade, tumor size, age)—that improved prognosis for invasive disease–free survival vs RS alone...
Maintenance Therapy After Induction With RVd With or Without Isatuximab in Transplant-Eligible Newly Diagnosed Multiple Myeloma
As reported in the Journal of Clinical Oncology by Mai et al, the German phase III GMMG-HD7 trial (Part 1) showed that the addition of isatuximab (Isa) to standard-of-care lenalidomide/bortezomib/dexamethasone (RVd) improved progression-free survival irrespective of maintenance therapy strategy in...
Studies Point to the Role of Diet in Hematologic Malignancies
According to research reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, a link seems to exist between hematologic malignancies and dietary components. The speakers said their studies may ultimately lead to dietary interventions that could alter the course of ...
NPM1 Genotypes and Outcomes in AML
In an AIEOP-BFM and COG-SWOG intergroup collaborative study reported in the Journal of Clinical Oncology, Tregnago et al found that patients with acute myeloid leukemia (AML) with NPM1 type D variants had significantly poorer event-free and overall survival vs those with non-D variants. Study...
Nuclear Speckle Signatures in Clear Cell RCC
Researchers have found a possible source of the variability in patterns of clear cell renal cell carcinoma (RCC), the most common kidney cancer diagnosed in adults. Katherine Alexander, PhD, Assistant Professor at Cold Spring Harbor Laboratory, and Shelley Berger, PhD, Professor at the University...
AI May Improve Ovarian Cancer Diagnoses
A new international study led by researchers at Karolinska Institutet in Sweden shows that AI-based models can outperform human experts at identifying ovarian cancer in ultrasound images. The study is published in Nature Medicine. “Ovarian tumors are common and are often detected by chance,” said...
FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection
On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indications as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab...
Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma
A primary analysis of ZUMA-2, reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, demonstrated durable responses to brexucabtagene autoleucel in patients with Bruton’s tyrosine kinase (BTK) inhibitor–naive mantle cell lymphoma. The findings from cohort 3 of...
FDA Grants Accelerated Approval to Encorafenib Combination for BRAF V600E–Mutant Metastatic Colorectal Cancer
On December 20, 2024, the U.S. Food and Drug Administration granted accelerated approval to encorafenib (Braftovi) in combination with cetuximab and modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected...
SEQUOIA 5-Year Follow-up: Zanubrutinib vs Bendamustine/Rituximab in Treatment-Naive CLL/SLL
As reported in the Journal of Clinical Oncology by Shadman et al, 5-year follow-up of the phase III SEQUOIA trial demonstrated that zanubrutinib continued to show a progression-free survival benefit over bendamustine plus rituximab in previously untreated patients with chronic lymphocytic...
CTX130 CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoma
In a phase I dose-escalation study (COBALT-LYM) reported in The Lancet Oncology, Iyer et al found that CTX130 (volamcabtagene durzigedleucel)—a CD70-directed, allogeneic chimeric antigen receptor (CAR) immunotherapy manufactured from healthy donor T cells—had a manageable safety profile and showed...
Long-Term Overall Survival With Adjuvant Gemcitabine/Capecitabine vs Gemcitabine in Pancreatic Adenocarcinoma
In a long-term analysis of the phase III ESPAC4 trial reported in Journal of Clinical Oncology, Palmer et al found adjuvant gemcitabine/capecitabine (Gem/Cap) was associated with prolonged overall survival vs gemcitabine monotherapy in patients with pancreatic adenocarcinoma. Study Details In...
Patient With Transfusion-Dependent Myelofibrosis and Severe Thrombocytopenia
This is Part 3 of Personalizing Therapy for Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Andrew Kuykendall, Anthony Hunter, and Stephen Oh discuss the management of a transfusion-dependent patient with...
Patient With Ruxolitinib-Treated Myelofibrosis Who Develops Anemia
This is Part 2 of Personalizing Therapy for Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Andrew Kuykendall, Anthony Hunter, and Stephen Oh discuss the management of a patient with myelofibrosis who develops...
Patient With Newly Diagnosed Myelofibrosis and Moderate Anemia
This is Part 1 of Personalizing Therapy for Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Andrew Kuykendall, Anthony Hunter, and Stephen Oh discuss the first-line treatment of a newly diagnosed patient with...
Study Finds Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders
First responders who worked at Ground Zero in the aftermath of the 2001 attacks on the World Trade Center in New York City were three times more likely to have genetic changes associated with an increased risk of leukemia compared with other first responders or members of the public who were not...
MRI-First Strategy May Be Safe for Prostate Cancer Detection
Researchers have examined whether a magnetic resonance imaging (MRI)-first approach is safe for prostate cancer detection over the long term, according to a recent study published by Hamm et al in JAMA Oncology. Background Several strategies may be deployed for the early detection of prostate...
Addition of SBRT to Systemic Therapy May Improve Outcomes in Select Patients With Locally Advanced Hepatocellular Carcinoma
The addition of stereotactic body radiotherapy (SBRT) to systemic therapy with sorafenib may improve progression-free survival and time-to-progression in patients with locally advanced hepatocellular carcinoma compared with sorafenib alone, according to a novel study published by Dawson et al in...
Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL
At the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 883), Alexey Danilov, MD, PhD, of the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope National Medical Center, Duarte, California, reported that single-agent epcoritamab led...
Use of Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia
In a German phase III trial (CLL12), reported in the Journal of Clinical Oncology, Langerbeins et al found that ibrutinib prolonged the time to symptomatic disease in patients with early-stage chronic lymphocytic leukemia (CLL) vs placebo. However, no differences in overall survival were observed....
Allison Betof Warner, MD, PhD, on TIL Therapy for Advanced Melanoma: Innovative Clinical Advances in Treatment
Allison Betof Warner, MD, PhD, reviews important clinical research in the treatment of advanced melanoma, including tumor-infiltrating lymphocyte (TIL) therapy, the role of this innovative treatment in advanced melanoma, and relevant data, peer-reviewed literature, and FDA approvals in 2024. She...
Influence of Social Networks Among Older Patients With Cancer
Researchers have received a $3.5 million grant from the National Cancer Institute to examine the impact of social networks on the decision-making process among older patients with cancer. Background Many individuals have social networks, which includes those who offer a connection and have similar...
Mesenchymal Cell Therapy Approved for Steroid-Refractory Acute GVHD
The U.S. Food and Drug Administration (FDA) recently approved remestemcel-L-rknd (Ryoncil), an allogeneic bone marrow–derived mesenchymal stromal cell therapy for steroid-refractory acute graft-vs-host disease (GVHD) in pediatric patients 2 months of age and older. The application received Orphan...
ASCO Elects 2026–2027 President, Six New Members of Board of Directors, Nominating Committee
ASCO announced the election of Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO, to lead as its President beginning in June 2026, as well as an additional six ASCO members to serve on its Board of Directors and Nominating Committee. 2026–2027 ASCO President-Elect Dr. Mittendorf, a long-time ASCO...
Detection of Occult Maternal Cancer Through Prenatal Cell-Free DNA Sequencing
In the IDENTIFY study, reported in The New England Journal of Medicine, Turriff et al found a high incidence of maternal occult cancer associated with unusual or nonreportable prenatal cell-free DNA (cfDNA) findings in fetal aneuploidy screening. Study Details In the ongoing study, performed at the ...
Alpelisib Plus Fulvestrant in PIK3CA-Mutated, Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer After Previous Therapy
In a cohort of a phase II study (BYLieve) reported in The Lancet Oncology, Rugo et al found that the PI3Kα inhibitor alpelisib plus the hormone therapy fulvestrant showed activity in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced breast cancer after disease...
FDA Approves Ensartinib for ALK- Positive Locally Advanced or Metastatic NSCLC
On December 18, 2024, the U.S. Food and Drug Administration (FDA) approved the anaplastic lymphoma kinase (ALK) inhibitor ensartinib (Ensacove) for adults with ALK-positive locally advanced or metastatic non–small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor. For full...
CAR T-Cell Therapy for Relapsed/Refractory Mantle Cell Lymphoma: ZUMA-2
Long-term follow-up of patients in ZUMA-2 cohorts 1 and 2 showed that 39% of patients with relapsed/refractory mantle cell lymphoma were alive after 5 years; patients in these cohorts received brexucabtagene autoleucel, the only chimeric antigen receptor (CAR) T-cell therapy to have 5-year...
Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma
A primary analysis of ZUMA-2, reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, demonstrated durable responses to brexucabtagene autoleucel in patients with Bruton’s tyrosine kinase (BTK) inhibitor–naive mantle cell lymphoma. The findings from cohort 3 of...
Unresectable Locally Advanced KRAS-Mutant NSCLC
This is Part 3 of Clinical Perspectives on KRAS-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Gregory Riely, Rebecca Heist, and Joshua Sabari discuss the management of a patient with unresectable locally...
Second-Line Treatment of KRAS-Mutant Metastatic NSCLC
This is Part 2 of Clinical Perspectives on KRAS-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Gregory Riely, Rebecca Heist, and Joshua Sabari discuss the second-line treatment of a patient with KRAS-mutant...
First-Line Treatment of KRAS-Mutant NSCLC
This is Part 1 of Clinical Perspectives on KRAS-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Gregory Riely, Rebecca Heist, and Joshua Sabari discuss the first-line treatment of a patient with KRAS-mutant...
Researchers May Have Uncovered Protein That Helps Cancer Cells Dodge CAR T-Cell Therapy
Researchers may have discovered a factor contributing to cancer cell evasion of chimeric antigen receptor (CAR) T-cell therapy, according to a recent study published by Chen et al in Cell. The findings could lead to more personalized therapies that improve survival among patients with cancer....
UICC, ICCP: Landmark Review of National Cancer Strategies Illuminates Progress, Persistent Challenges
The Union for International Cancer Control (UICC) has examined the National Cancer Control Plans and reported their findings in a new comprehensive global review published by Romero et al in The Lancet Oncology. The findings will be presented at the Cancer Planners Forum in May 2025 in Geneva,...
Larotrectinib in Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors
In a Children’s Oncology Group study (ADVL1823) reported in Journal of Clinical Oncology, Laetsch et al found that larotrectinib was highly active in patients with newly diagnosed infantile fibrosarcoma and other pediatric NTRK fusion–positive solid tumors. Study Details The U.S. multicenter trial...
Novel Formulation Used in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting
In a Chinese phase III trial (PROFIT) reported in Journal of Clinical Oncology, Zhou et al found that mixed-formulation fosrolapitant/palonosetron (HR20013) plus dexamethasone was noninferior to individually dosed fosrolapitant plus palonosetron plus dexamethasone in preventing chemotherapy-induced ...
Primary Lung Tumor SBRT Followed by Concurrent Mediastinal Chemoradiotherapy and Immunotherapy Consolidation in Locally Advanced NSCLC
In a phase II trial reported in The Lancet Oncology, Heinzerling et al found evidence of efficacy of primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemotherapy and consolidative immunotherapy in patients with locally advanced non–small cell lung cancer...
CBD May Not Reduce Scan-Related Anxiety in Patients With Advanced Breast Cancer
Cannabidiol (CBD) may not significantly change scan-related anxiety compared with placebo in patients with advanced breast cancer but may result in lower overall anxiety levels, according to a recent study published by Nayak et al in JAMA Network Open. Background Anxiety is common among adult...
